BIOGEN INC (1BIIB.MI) Stock Fundamental Analysis
Europe - BIT:1BIIB - US09062X1037 - Common Stock
132.15 EUR
+8.15 (+6.57%)
Taking everything into account, 1BIIB scores 5 out of 10 in our fundamental rating. 1BIIB was compared to 76 industry peers in the Biotechnology industry. 1BIIB has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. 1BIIB has a bad growth rate and is valued cheaply. With these ratings, 1BIIB could be worth investigating further for value investing!.
1. Profitability
1.1 Basic Checks
1BIIB had positive earnings in the past year.
In the past year 1BIIB had a positive cash flow from operations.
1BIIB had positive earnings in each of the past 5 years.
1BIIB had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of 1BIIB (5.40%) is better than 82.89% of its industry peers.
1BIIB's Return On Equity of 8.68% is amongst the best of the industry. 1BIIB outperforms 84.21% of its industry peers.
Looking at the Return On Invested Capital, with a value of 9.52%, 1BIIB belongs to the top of the industry, outperforming 88.16% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for 1BIIB is below the industry average of 12.82%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.4% | ||
| ROE | 8.68% | ||
| ROIC | 9.52% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
1.3 Margins
1BIIB's Profit Margin of 15.31% is amongst the best of the industry. 1BIIB outperforms 85.53% of its industry peers.
In the last couple of years the Profit Margin of 1BIIB has declined.
1BIIB's Operating Margin of 27.35% is amongst the best of the industry. 1BIIB outperforms 88.16% of its industry peers.
1BIIB's Operating Margin has declined in the last couple of years.
The Gross Margin of 1BIIB (75.43%) is better than 69.74% of its industry peers.
In the last couple of years the Gross Margin of 1BIIB has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.35% | ||
| PM (TTM) | 15.31% | ||
| GM | 75.43% |
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), 1BIIB is creating some value.
Compared to 1 year ago, 1BIIB has more shares outstanding
Compared to 5 years ago, 1BIIB has less shares outstanding
The debt/assets ratio for 1BIIB has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 3.12 indicates that 1BIIB is not in any danger for bankruptcy at the moment.
1BIIB has a better Altman-Z score (3.12) than 76.32% of its industry peers.
The Debt to FCF ratio of 1BIIB is 3.40, which is a good value as it means it would take 1BIIB, 3.40 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of 1BIIB (3.40) is better than 84.21% of its industry peers.
A Debt/Equity ratio of 0.36 indicates that 1BIIB is not too dependend on debt financing.
The Debt to Equity ratio of 1BIIB (0.36) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.36 | ||
| Debt/FCF | 3.4 | ||
| Altman-Z | 3.12 |
ROIC/WACC1.16
WACC8.22%
2.3 Liquidity
1BIIB has a Current Ratio of 2.50. This indicates that 1BIIB is financially healthy and has no problem in meeting its short term obligations.
1BIIB has a Current ratio (2.50) which is comparable to the rest of the industry.
A Quick Ratio of 1.79 indicates that 1BIIB should not have too much problems paying its short term obligations.
The Quick ratio of 1BIIB (1.79) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.5 | ||
| Quick Ratio | 1.79 |
3. Growth
3.1 Past
The earnings per share for 1BIIB have decreased by -3.61% in the last year.
1BIIB shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -13.31% yearly.
The Revenue has been growing slightly by 3.36% in the past year.
Measured over the past years, 1BIIB shows a decrease in Revenue. The Revenue has been decreasing by -7.62% on average per year.
EPS 1Y (TTM)-3.61%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%3.6%
Revenue 1Y (TTM)3.36%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%7.33%
3.2 Future
The Earnings Per Share is expected to grow by 1.15% on average over the next years.
Based on estimates for the next years, 1BIIB will show a decrease in Revenue. The Revenue will decrease by -0.44% on average per year.
EPS Next Y-2.25%
EPS Next 2Y-0.87%
EPS Next 3Y0.6%
EPS Next 5Y1.15%
Revenue Next Year0.43%
Revenue Next 2Y-1.77%
Revenue Next 3Y-1.1%
Revenue Next 5Y-0.44%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 9.49, the valuation of 1BIIB can be described as reasonable.
92.11% of the companies in the same industry are more expensive than 1BIIB, based on the Price/Earnings ratio.
1BIIB's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.03.
The Price/Forward Earnings ratio is 9.38, which indicates a very decent valuation of 1BIIB.
Based on the Price/Forward Earnings ratio, 1BIIB is valued cheaply inside the industry as 96.05% of the companies are valued more expensively.
1BIIB's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.27.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.49 | ||
| Fwd PE | 9.38 |
4.2 Price Multiples
1BIIB's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. 1BIIB is cheaper than 89.47% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of 1BIIB indicates a rather cheap valuation: 1BIIB is cheaper than 92.11% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 12.06 | ||
| EV/EBITDA | 7.41 |
4.3 Compensation for Growth
1BIIB has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-0.87%
EPS Next 3Y0.6%
5. Dividend
5.1 Amount
No dividends for 1BIIB!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIT:1BIIB (10/31/2025, 7:00:00 PM)
132.15
+8.15 (+6.57%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners92.49%
Inst Owner ChangeN/A
Ins Owners0.14%
Ins Owner ChangeN/A
Market Cap19.37B
Revenue(TTM)10.00B
Net Income(TTM)1.53B
Analysts73.81
Price Target148.02 (12.01%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)28.1%
Min EPS beat(2)17.28%
Max EPS beat(2)38.92%
EPS beat(4)4
Avg EPS beat(4)15.59%
Min EPS beat(4)0.67%
Max EPS beat(4)38.92%
EPS beat(8)8
Avg EPS beat(8)13.06%
EPS beat(12)12
Avg EPS beat(12)11.49%
EPS beat(16)14
Avg EPS beat(16)10.96%
Revenue beat(2)2
Avg Revenue beat(2)9.15%
Min Revenue beat(2)6.67%
Max Revenue beat(2)11.62%
Revenue beat(4)3
Avg Revenue beat(4)4.43%
Min Revenue beat(4)-0.68%
Max Revenue beat(4)11.62%
Revenue beat(8)5
Avg Revenue beat(8)1.84%
Revenue beat(12)8
Avg Revenue beat(12)1.78%
Revenue beat(16)11
Avg Revenue beat(16)1.73%
PT rev (1m)0.98%
PT rev (3m)-5.06%
EPS NQ rev (1m)0.91%
EPS NQ rev (3m)-4.82%
EPS NY rev (1m)-0.56%
EPS NY rev (3m)5.28%
Revenue NQ rev (1m)-0.08%
Revenue NQ rev (3m)1.84%
Revenue NY rev (1m)0.03%
Revenue NY rev (3m)4.44%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.49 | ||
| Fwd PE | 9.38 | ||
| P/S | 2.23 | ||
| P/FCF | 12.06 | ||
| P/OCF | 10.52 | ||
| P/B | 1.26 | ||
| P/tB | 13.3 | ||
| EV/EBITDA | 7.41 |
EPS(TTM)13.93
EY10.54%
EPS(NY)14.08
Fwd EY10.66%
FCF(TTM)10.96
FCFY8.29%
OCF(TTM)12.56
OCFY9.51%
SpS59.34
BVpS104.67
TBVpS9.93
PEG (NY)N/A
PEG (5Y)N/A
Graham Number181.13
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.4% | ||
| ROE | 8.68% | ||
| ROCE | 10.87% | ||
| ROIC | 9.52% | ||
| ROICexc | 10.7% | ||
| ROICexgc | 37.26% | ||
| OM | 27.35% | ||
| PM (TTM) | 15.31% | ||
| GM | 75.43% | ||
| FCFM | 18.47% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
ROICexc(3y)12.43%
ROICexc(5y)16.11%
ROICexgc(3y)38.35%
ROICexgc(5y)40.12%
ROCE(3y)12.07%
ROCE(5y)15.58%
ROICexgc growth 3Y14.15%
ROICexgc growth 5Y-5.35%
ROICexc growth 3Y-15.93%
ROICexc growth 5Y-20.8%
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
F-Score6
Asset Turnover0.35
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.36 | ||
| Debt/FCF | 3.4 | ||
| Debt/EBITDA | 1.81 | ||
| Cap/Depr | 36.28% | ||
| Cap/Sales | 2.7% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 60.86% | ||
| Profit Quality | 120.66% | ||
| Current Ratio | 2.5 | ||
| Quick Ratio | 1.79 | ||
| Altman-Z | 3.12 |
F-Score6
WACC8.22%
ROIC/WACC1.16
Cap/Depr(3y)54.43%
Cap/Depr(5y)68.89%
Cap/Sales(3y)3.09%
Cap/Sales(5y)3.21%
Profit Quality(3y)99.34%
Profit Quality(5y)120.98%
High Growth Momentum
Growth
EPS 1Y (TTM)-3.61%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%3.6%
EPS Next Y-2.25%
EPS Next 2Y-0.87%
EPS Next 3Y0.6%
EPS Next 5Y1.15%
Revenue 1Y (TTM)3.36%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%7.33%
Revenue Next Year0.43%
Revenue Next 2Y-1.77%
Revenue Next 3Y-1.1%
Revenue Next 5Y-0.44%
EBIT growth 1Y23.31%
EBIT growth 3Y-8.8%
EBIT growth 5Y-18.9%
EBIT Next Year7.73%
EBIT Next 3Y2.84%
EBIT Next 5Y5.8%
FCF growth 1Y64.41%
FCF growth 3Y-9.06%
FCF growth 5Y-17.06%
OCF growth 1Y48.2%
OCF growth 3Y-7.56%
OCF growth 5Y-16.49%
BIOGEN INC / 1BIIB.MI FAQ
What is the ChartMill fundamental rating of BIOGEN INC (1BIIB.MI) stock?
ChartMill assigns a fundamental rating of 5 / 10 to 1BIIB.MI.
What is the valuation status for 1BIIB stock?
ChartMill assigns a valuation rating of 7 / 10 to BIOGEN INC (1BIIB.MI). This can be considered as Undervalued.
Can you provide the profitability details for BIOGEN INC?
BIOGEN INC (1BIIB.MI) has a profitability rating of 7 / 10.
What is the earnings growth outlook for BIOGEN INC?
The Earnings per Share (EPS) of BIOGEN INC (1BIIB.MI) is expected to decline by -2.25% in the next year.